Jinyu Shi, Li Zhou, Hui-Si Huang, Liyuan Peng, Na Xie, Edouard Nice, Li Fu, Cen Jiang, Canhua Huang
International journal of biological sciences 2022Colorectal cancer (CRC) is one of the most common malignancies worldwide, yet successful treatment still remains a challenge. In this study, we found that oxiconazole (OXI), a broad-spectrum antifungal agent, exhibits certain anti-tumor effect against CRC. Autophagy arrest and subsequent apoptosis are characterized as pivotal events involving OXI-induced growth suppression of CRC cells. Mechanistically, OXI downregulates the protein levels of peroxiredoxin-2 (PRDX2), an antioxidant enzyme, for reactive oxygen species (ROS) detoxication, to initiate autophagy by inactivating the Akt/mTOR pathway and inhibiting RAB7A-mediated fusion of autophagosome and lysosome, which lead to extreme accumulation of autophagosomes and subsequent growth suppression of CRC cells. Consistently, interfering with autophagy or overexpressing PRDX2 significantly impedes OXI-induced growth suppression of CRC cells. Moreover, OXI plus oxaliplatin, a mainstay drug for CRC treatment, achieves an improved anti-tumor effect. Taken together, our findings bring novel mechanistic insights into OXI-induced autophagy arrest and the growth inhibitory effect on CRC cells, and suggest a promisingly therapeutic role of OXI for CRC treatment. © The author(s).
Jinyu Shi, Li Zhou, Hui-Si Huang, Liyuan Peng, Na Xie, Edouard Nice, Li Fu, Cen Jiang, Canhua Huang. Repurposing Oxiconazole against Colorectal Cancer via PRDX2-mediated Autophagy Arrest. International journal of biological sciences. 2022;18(9):3747-3761
PMID: 35813474
View Full Text